Detalles de la búsqueda
1.
Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial.
J Am Acad Dermatol
; 78(6): 1156-1163, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29409914
2.
WITHDRAWN: Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 2 phase 3, 29-day, randomized, controlled REVEAL trials.
J Am Acad Dermatol
; 2018 Jan 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-29409915
3.
Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the Second REVEAL Trial.
J Drugs Dermatol
; 17(3): 290-298, 2018 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29537447
4.
Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial.
J Drugs Dermatol
; 17(1): 97-105, 2018 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29320594
5.
Topical Oxymetazoline Cream 1.0% for Persistent Facial Erythema Associated With Rosacea: Pooled Analysis of the Two Phase 3, 29-Day, Randomized, Controlled REVEAL Trials
J Drugs Dermatol
; 17(11): 1201-1208, 2018 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30500142
6.
A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19.
Eur Respir J
; 58(4)2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34210790
7.
Bimatoprost 0.03% for the Treatment of Eyebrow Hypotrichosis.
Dermatol Surg
; 42(5): 608-17, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-27124878
8.
Resveratrol and para-coumarate serve as ring precursors for coenzyme Q biosynthesis.
J Lipid Res
; 56(4): 909-19, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25681964
9.
A Prospective, Nonrandomized, Open-Label Study of the Efficacy and Safety of OnabotulinumtoxinA in Adolescents with Primary Axillary Hyperhidrosis.
Pediatr Dermatol
; 32(5): 609-17, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26059781
10.
Patient-reported outcomes of bimatoprost for eyelash growth: results from a randomized, double-masked, vehicle-controlled, parallel-group study.
Aesthet Surg J
; 33(6): 789-98, 2013 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23873891
11.
Delayed accumulation of intestinal coliform bacteria enhances life span and stress resistance in Caenorhabditis elegans fed respiratory deficient E. coli.
BMC Microbiol
; 12: 300, 2012 Dec 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-23256533
12.
Eyelash growth in subjects treated with bimatoprost: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study.
J Am Acad Dermatol
; 66(5): 801-6, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21899919
13.
CELER: A 365-Participant Corpus of Eye Movements in L1 and L2 English Reading.
Open Mind (Camb)
; 6: 41-50, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36439073
14.
Intraperitoneal and Extraperitoneal Colonic Perforation Following Diagnostic and Therapeutic Colonoscopy with Crohn's-related Stricture Dilation.
Cureus
; 12(3): e7162, 2020 Mar 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32257705
15.
Safety and Efficacy of Bimatoprost for Eyelash Growth in Postchemotherapy Subjects.
J Clin Aesthet Dermatol
; 8(4): 11-20, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26060513
16.
Bimatoprost 0.03% for the Treatment of Eyelash Hypotrichosis: A Pooled Safety Analysis of Six Randomized, Double-masked Clinical Trials.
J Clin Aesthet Dermatol
; 8(7): 17-29, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26203317
17.
Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials.
Clin Ophthalmol
; 5: 759-65, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21691584
Resultados
1 -
17
de 17
1
Próxima >
>>